Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou
Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta